The acquisition of Amylin Pharmaceutical’s (AMLN +0.1%) by AstraZeneca (AZN +0.1%) and...

The acquisition of Amylin Pharmaceutical’s (AMLN +0.1%) by AstraZeneca (AZN +0.1%) and Bristol-Myers Squibb (BMY -1.8%) this weekend has only whetted AZN's appetite for more purchases, says interim CEO Simon Lowth. The chief executive says the joint purchase reduces the drug giant's capital costs, and creates more flexibility for pipeline development and searching out new products, noting it has the cash and resources to make more acquisitions.